Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
168.92 (1y: +21%)
Market Cap 93.78 B P/E(ttm) 25.40
Enterprise Value 93.48 B P/B 14.80
NVO- NYSE (USA)
Novo Nordisk A/S
  • Currently 1/5
Business Predictability Rank: 1-Star
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$168.92
Switch to:

GuruFocus Financial Strength Rank measures how strong a companyÂ’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry		 vs
history
Cash to Debt 20.518
NVO's Cash to Debt is ranked lower than
56% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NVO: 20.518 )
NVO' s 10-Year Cash to Debt Range
Min: 0.41   Max: 20.52
Current: 20.52
0.41
20.52
Equity to Asset 0.556
NVO's Equity to Asset is ranked lower than
53% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 0.54 vs. NVO: 0.556 )
NVO' s 10-Year Equity to Asset Range
Min: 0.56   Max: 0.73
Current: 0.56
0.56
0.73
Interest Coverage 16.9
NVO's Interest Coverage is ranked lower than
60% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NVO: 16.9 )
NVO' s 10-Year Interest Coverage Range
Min: 11   Max: No Debt
Current: 16.9
F-Score: 7
Z-Score: 16.72
M-Score: -2.46
GuruFocus Profitability Rank ranks how profitable a company is and how likely the companyÂ’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry		 vs
history
Operating margin (%) 36.10
NVO's Operating margin (%) is ranked higher than
94% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -52.55 vs. NVO: 36.10 )
NVO' s 10-Year Operating margin (%) Range
Min: 17.3   Max: 36.1
Current: 36.1
17.3
36.1
Net-margin (%) 27.5
NVO's Net-margin (%) is ranked higher than
91% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -55.70 vs. NVO: 27.5 )
NVO' s 10-Year Net-margin (%) Range
Min: 11.5   Max: 27.5
Current: 27.5
11.5
27.5
ROE (%) 52.7
NVO's ROE (%) is ranked higher than
97% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -16.60 vs. NVO: 52.7 )
NVO' s 10-Year ROE (%) Range
Min: 13   Max: 52.7
Current: 52.7
13
52.7
ROA (%) 32.6
NVO's ROA (%) is ranked higher than
96% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -14.40 vs. NVO: 32.6 )
NVO' s 10-Year ROA (%) Range
Min: 7.8   Max: 32.6
Current: 32.6
7.8
32.6
ROC (Joel Greenblatt) (%) 78.10
NVO's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -0.20 vs. NVO: 78.10 )
NVO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 15.6   Max: 99
Current: 78.1
15.6
99
Revenue Growth (%) 13.7
NVO's Revenue Growth (%) is ranked higher than
84% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -1.40 vs. NVO: 13.7 )
NVO' s 10-Year Revenue Growth (%) Range
Min: -8.4   Max: 26.9
Current: 13.7
-8.4
26.9
EBITDA Growth (%) 17.9
NVO's EBITDA Growth (%) is ranked higher than
91% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -11.35 vs. NVO: 17.9 )
NVO' s 10-Year EBITDA Growth (%) Range
Min: -8   Max: 32.6
Current: 17.9
-8
32.6
EPS Growth (%) 21.5
NVO's EPS Growth (%) is ranked higher than
90% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -8.70 vs. NVO: 21.5 )
NVO' s 10-Year EPS Growth (%) Range
Min: -3.3   Max: 36.6
Current: 21.5
-3.3
36.6
» NVO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

NVO Guru Trades in Q2 2012

Ken Fisher 2,786,828 sh (+519.97%)
Steven Cohen 4,900 sh (+32.43%)
Jim Simons 1,759,300 sh (+1.71%)
Tom Gayner 228,900 sh (+0.84%)
John Hussman 3,000 sh (unchged)
Murray Stahl 1,548 sh (unchged)
Mario Gabelli 5,445 sh (-0.82%)
» More
Q3 2012

NVO Guru Trades in Q3 2012

Steven Cohen 7,700 sh (+57.14%)
Jim Simons 2,010,500 sh (+14.28%)
Murray Stahl 1,548 sh (unchged)
John Hussman Sold Out
Tom Gayner 228,100 sh (-0.35%)
Ken Fisher 2,761,970 sh (-0.89%)
Mario Gabelli 5,000 sh (-8.17%)
» More
Q4 2012

NVO Guru Trades in Q4 2012

Jim Simons 2,331,800 sh (+15.98%)
Murray Stahl 1,548 sh (unchged)
Tom Gayner 227,300 sh (-0.35%)
Ken Fisher 2,663,631 sh (-3.56%)
Mario Gabelli 4,370 sh (-12.6%)
Steven Cohen 4,671 sh (-39.34%)
» More
Q1 2013

NVO Guru Trades in Q1 2013

Jim Simons 2,627,600 sh (+12.69%)
Steven Cohen 4,800 sh (+2.76%)
Ken Fisher 2,666,637 sh (+0.11%)
Murray Stahl 1,548 sh (unchged)
Tom Gayner 226,400 sh (-0.4%)
Mario Gabelli 1,734 sh (-60.32%)
» More
» Details

Insider Trades

Latest Guru Trades with NVO

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Mario Gabelli 2013-03-31 Reduce -60.32%$161.2 - $194.3 $ 168.92-3%1734
John Hussman 2012-09-30 Sold Out 0.01%$144.15 - $160.77 $ 168.9210%0
John Hussman 2012-03-31 Reduce -40%$115.46 - $144.71 $ 168.9236%3000
Mario Gabelli 2011-12-31 Add 66.87%$94.58 - $115.26 $ 168.9257%5590
John Hussman 2011-09-30 New Buy0.01%$97.31 - $127.27 $ 168.9252%5000
John Keeley 2011-06-30 Sold Out 0.01%$117.02 - $131.43 $ 168.9236%0
Mario Gabelli 2011-06-30 Reduce -21.18%$117.02 - $131.43 $ 168.9236%3350
John Keeley 2010-12-31 New Buy0.01%$90.99 - $112.17 $ 168.9263%2780
Vanguard Health Care Fund 2010-09-30 Sold Out 0.19%$81.13 - $99.24 $ 168.9292%0
Mario Gabelli 2010-09-30 Reduce -28.77%$81.13 - $99.24 $ 168.9292%4420
Vanguard Health Care Fund 2010-06-30 Reduce -42.86%0.08%$74.02 - $85.32 $ 168.92112%400000
Mario Gabelli 2010-06-30 Reduce -56.26%$74.02 - $85.32 $ 168.92112%6205
Tom Gayner 2010-03-31 Add 39.04%0.31%$63.85 - $79.13 $ 168.92138%231500
Vanguard Health Care Fund 2010-03-31 Reduce -12.5%0.04%$63.85 - $79.13 $ 168.92138%700000
Premium More recent guru trades are included for Premium Members only!!

Ratios

vs
industry		 vs
history
P/E(ttm) 25.40
NVO's P/E(ttm) is ranked higher than
68% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 20.85 vs. NVO: 25.40 )
NVO' s 10-Year P/E(ttm) Range
Min: 7.54   Max: 40.45
Current: 25.4
7.54
40.45
P/B 14.80
NVO's P/B is ranked lower than
81% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. NVO: 14.80 )
NVO' s 10-Year P/B Range
Min: 0.62   Max: 16.59
Current: 14.8
0.62
16.59
P/S 7.00
NVO's P/S is ranked lower than
52% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 6.90 vs. NVO: 7.00 )
NVO' s 10-Year P/S Range
Min: 1.19   Max: 7.59
Current: 7
1.19
7.59
PFCF 29.80
NVO's PFCF is ranked higher than
67% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 24.02 vs. NVO: 29.80 )
NVO' s 10-Year PFCF Range
Min: 4.55   Max: 121.51
Current: 29.8
4.55
121.51
EV-to-EBIT 19.2
NVO's EV-to-EBIT is ranked higher than
63% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 14.61 vs. NVO: 19.2 )
NVO' s 10-Year EV-to-EBIT Range
Min: 1.9   Max: 63.6
Current: 19.2
1.9
63.6
PEG 1.1
NVO's PEG is ranked higher than
98% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 1.35 vs. NVO: 1.1 )
NVO' s 10-Year PEG Range
Min: 0.08   Max: 9.91
Current: 1.1
0.08
9.91
Shiller P/E 39.5
NVO's Shiller P/E is ranked higher than
100% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. NVO: 39.5 )
NVO' s 10-Year Shiller P/E Range
Min: 10.58   Max: 42.95
Current: 39.5
10.58
42.95

Dividend & Buy Back

vs
industry		 vs
history
Dividend Yield 1.30
NVO's Dividend Yield is ranked higher than
89% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 1.19 vs. NVO: 1.30 )
NVO' s 10-Year Dividend Yield Range
Min: 0.79   Max: 5.65
Current: 1.3
0.79
5.65
Dividend Payout 0.3
NVO's Dividend Payout is ranked higher than
91% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 0.93 vs. NVO: 0.3 )
NVO' s 10-Year Dividend Payout Range
Min: 0.13   Max: 1.15
Current: 0.3
0.13
1.15
Dividend growth (3y) 13.8
NVO's Dividend growth (3y) is ranked higher than
99% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -15.00 vs. NVO: 13.8 )
NVO' s 10-Year Dividend growth (3y) Range
Min: -24.1   Max: 18.9
Current: 13.8
-24.1
18.9
Yield on cost (5-Year) 3.19
NVO's Yield on cost (5-Year) is ranked higher than
94% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 1.29 vs. NVO: 3.19 )
NVO' s 10-Year Yield on cost (5-Year) Range
Min: 1.94   Max: 13.88
Current: 3.19
1.94
13.88
Share Buyback Rate 2.3
NVO's Share Buyback Rate is ranked higher than
96% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -8.15 vs. NVO: 2.3 )
NVO' s 10-Year Share Buyback Rate Range
Min: 16.4   Max: -17.2
Current: 2.3

Valuation & Return

vs
industry		 vs
history
Price/Net Cash 42.8
NVO's Price/Net Cash is ranked lower than
286533% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 8.80 vs. NVO: 42.8 )
NVO' s 10-Year Price/Net Cash Range
Min: 0   Max: 0
Current: 42.8
Price/Net Current Asset Value 38.6
NVO's Price/Net Current Asset Value is ranked lower than
54% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 32.60 vs. NVO: 38.6 )
NVO' s 10-Year Price/Net Current Asset Value Range
Min: 5.5   Max: 33.9
Current: 38.6
5.5
33.9
Price/Tangible Book 15.2
NVO's Price/Tangible Book is ranked lower than
61% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 4.70 vs. NVO: 15.2 )
NVO' s 10-Year Price/Tangible Book Range
Min: 1.6   Max: 12.9
Current: 15.2
1.6
12.9
Price/DCF (Projected) 2.2
NVO's Price/DCF (Projected) is ranked higher than
93% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 2.00 vs. NVO: 2.2 )
NVO' s 10-Year Price/DCF (Projected) Range
Min: 0.3   Max: 2.6
Current: 2.2
0.3
2.6
Price/Median PS Value 2
NVO's Price/Median PS Value is ranked higher than
62% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 0.90 vs. NVO: 2 )
NVO' s 10-Year Price/Median PS Value Range
Min: 0.4   Max: 1.9
Current: 2
0.4
1.9
Price/Peter Lynch Fair Value 1.2
NVO's Price/Peter Lynch Fair Value is ranked higher than
97% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 1.50 vs. NVO: 1.2 )
NVO' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.3   Max: 2.9
Current: 1.2
0.3
2.9
Price/Graham Number 2
NVO's Price/Graham Number is ranked higher than
97% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 1.95 vs. NVO: 2 )
NVO' s 10-Year Price/Graham Number Range
Min: 0.8   Max: 3.7
Current: 2
0.8
3.7
Earnings Yield (Greenblatt) 5.20
NVO's Earnings Yield (Greenblatt) is ranked lower than
71% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 8.00 vs. NVO: 5.20 )
NVO' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.6   Max: 52.8
Current: 5.2
1.6
52.8
Forward Rate of Return (Yacktman) 23.11
NVO's Forward Rate of Return (Yacktman) is ranked higher than
89% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -4.65 vs. NVO: 23.11 )
NVO' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -9   Max: 119.8
Current: 23.11
-9
119.8

Business Description

Novo Nordisk is a healthcare company engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The company operates in two business segments, diabetes care and biopharmaceuticals. The diabetes care segment covers insulin's, GLP-1, other protein-related products and projects such as glucagon and protein-related delivery systems, obesity and oral anti-diabetic drugs. The biopharmaceuticals segment covers the therapy areas of hemophilia, growth hormone therapy, hormone replacement therapy and inflammation. The company manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society.
Company Website
Industry: Biotechnology
Compare:AMGN, GILD, BIIB, CELG, CMXHY
Traded in other countries:NOVO B.Denmark, NONOF.USA, NOVA.Germany, NOVB.Germany

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial